AI FOR SCIENCE · ON THE RECORD
Converge Bio
Trains generative models on DNA, RNA and protein sequences and sells them to drug developers as finished systems for antibody design and optimisation, protein manufacturing yield, and target and biomarker discovery. Customers can fine-tune private copies on their own data.
Full funding record →On the timeline →People filter →
Recent timeline
People
Only people the AI4S.fyi record has named: in a round, a timeline entry, commentary, an interview or a sourced role. Not the full team.
Named on AI4S.fyi
Funding rounds tracked
- 2026-01-13Series A · $25MconfirmedLed by Bessemer Venture Partners · With TLV Partners, Vintage Investment Partners, Saras CapitalStated use: not itemised; the release ties the round to its commercial traction and scientific results
- 2024-11-20Seed · $5.5MconfirmedLed by TLV PartnersStated use: hiring, winning customers, a scientific paper on antibody design and training a foundation model
Each round links to its line on the funding record, with its source.
Also in Protein design on the funding board
The other companies the funding board files under the same field, latest round first. A list of what the record tracks, not a ranking or a market map.
- 2026-10-28BioGeometrySeries A+ · not disclosed; the A series to date tops $100MBuilds generative models for biology: GeoFlow, an all-atom model that predicts the structures of proteins and their complexes and designs binders, and GeoCell, a virtual-cell model of how cells' gene expression responds to genetic and drug perturbations. An automated lab expresses and tests the designs and feeds the data back. It designs antibodies, vaccines, peptides and enzymes for partners and its own pipeline, including synthetic-biology products.
- 2026-09-24BigHat BiosciencesSeries C · $75MDesigns antibodies with machine learning tied to a fast automated wet lab (Milliner) that makes and tests designs; its lead drug BHB810 is in the clinic.
- 2026-08-11Aureka BiotechnologiesSeries B · $100MDesigns antibodies with its own biological foundation model, AuraIDE (released in open form as OpenDDE), trained and retrained on data from its own single-cell functional screens.
- 2026-07-14Chai DiscoverySeries C · $400MBuilds AI models that predict how molecules bind and design antibodies from scratch, and licenses them to drugmakers as software.
- 2026-06-17MoleculeMindSeries A (extension) · A-series cumulative total over US$100 millionAI protein structure prediction and design (MoleculeOS, MMFold, MMDesign) sold to drugmakers and industrial-enzyme users, with a few in-house early programs.
- 2026-03-20Helixon (Earendil Labs)Round (unnamed) · $787MAI protein modelling plus high-throughput experiments to design antibodies, especially bispecifics, which it licenses to Sanofi and Genentech and develops in-house.
This page compiles what AI4S.fyi has recorded and links each item to its source. It is not a grade of the organization and not its complete history: a blank means the record has not caught up as often as it means nothing happened.